| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLK3 |
| Uniprot No | P49761 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-490aa |
| 氨基酸序列 | MHHCKRYRSPEPDPYLSYRWKRRRSYSREHEGRLRYPSRREPPPRRSRSRSHDRLPYQRR YRERRDSDTYRCEERSPSFGEDYYGPSRSRHRRRSRERGPYRTRKHAHHCHKRRTRSCSS ASSRSQQSSKRSSRSVEDDKEGHLVCRIGDWLQERYEIVGNLGEGTFGKVVECLDHARGK SQVALKIIRNVGKYREAARLEINVLKKIKEKDKENKFLCVLMSDWFNFHGHMCIAFELLG KNTFEFLKENNFQPYPLPHVRHMAYQLCHALRFLHENQLTHTDLKPENILFVNSEFETLY NEHKSCEEKSVKNTSIRVADFGSATFDHEHHTTIVATRHYRPPEVILELGWAQPCDVWSI GCILFEYYRGFTLFQTHENREHLVMMEKILGPIPSHMIHRTRKQKYFYKGGLVWDENSSD GRYVKENCKPLKSYMLQDSLEHVQLFDLMRRMLEFDPAQRITLAEALLHPFFAGLTPEER SFHTSRNPSR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是虚构的关于CLK3重组蛋白的参考文献示例：
1. **标题**：*Expression and Functional Characterization of Recombinant CLK3 Kinase in Mammalian Cells*
**作者**：Smith A, et al.
**摘要**：研究通过哺乳动物表达系统成功获得高活性CLK3重组蛋白，并验证其磷酸化SR蛋白的能力，揭示其在剪接调控中的关键作用。
2. **标题**：*Structural Insights into CLK3 Recombinant Protein: Implications for Inhibitor Design*
**作者**：Wang L, et al.
**摘要**：通过X射线晶体学解析CLK3重组蛋白的ATP结合域结构，为开发选择性激酶抑制剂提供分子基础。
3. **标题**：*CLK3 Recombinant Protein as a Therapeutic Target in Acute Myeloid Leukemia*
**作者**：Johnson R, et al.
**摘要**：发现CLK3重组蛋白在白血病细胞中异常激活，靶向其激酶活性可抑制肿瘤生长，提示其作为潜在治疗靶点。
4. **标题**：*Optimization of CLK3 Recombinant Protein Purification for High-Throughput Screening*
**作者**：Chen X, et al.
**摘要**：开发基于亲和层析的CLK3重组蛋白高效纯化方案，并用于大规模药物筛选，鉴定出多个新型小分子抑制剂。
(注：上述文献为虚构，仅作示例参考。)
CLK3 (CDC-like kinase 3) is a serine/threonine kinase belonging to the CLK (CDC2-like kinase) family, which regulates RNA splicing by phosphorylating key components of the spliceosome. It plays a critical role in modulating alternative splicing events, thereby influencing gene expression diversity in cellular processes such as differentiation, stress responses, and cell cycle progression. Structurally, CLK3 contains a conserved kinase domain and a unique N-terminal region that may mediate substrate interactions or subcellular localization. Unlike other CLK family members (CLK1. CLK2. CLK4), CLK3 exhibits distinct substrate preferences and regulatory mechanisms, though overlapping functions in splicing regulation are observed.
Dysregulation of CLK3 has been implicated in various diseases. Overexpression or aberrant activity is linked to cancer progression, particularly in leukemia and solid tumors, where it promotes oncogenic splicing variants. Conversely, reduced CLK3 function is associated with neurological disorders, including autism spectrum disorders, through disrupted splicing of synaptic proteins. These dual pathological roles highlight its context-dependent regulatory nature.
Recombinant CLK3 protein is typically produced in eukaryotic expression systems (e.g., insect or mammalian cells) to ensure proper post-translational modifications and kinase activity. Purified CLK3 serves as a vital tool for biochemical assays, inhibitor screening, and structural studies. Recent drug discovery efforts target CLK3 to develop small-molecule inhibitors for cancer therapy, capitalizing on its role in alternative splicing of survival-related genes. However, challenges remain in achieving selectivity over other CLK isoforms due to their structural similarities. Ongoing research continues to unravel CLK3's spliceosome-interacting networks and its therapeutic potential across diseases.
×
